Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics

Executive Summary

One project will look at tablet size, odor and other characteristics that in the past have been a source of public complaints about generics.

You may also be interested in...

Generic Pills Allowed Limited Size Differential In Draft Guidance

FDA cites concern about safety and patient adherence to therapy in draft guidance on the size, shape and other physical attributes of generic drugs.

FDA’s Generic Regulatory Science Plan Taking Broad-brush Approach So Far

Agency lists five topics for industry and stakeholders to focus on during a June 21 meeting on what its fiscal year 2014 priorities should be; among issues for consideration are prioritizing projects based on public health impact and identifying challenges that limit the availability of generic drugs.

GDUFA: FDA Sees High Fee Collection Rate After First Six Months

About 24% of facility fees and 20% of all fees are outstanding, but industry officials also want to measure success through FDA hiring and communication.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts